EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Shan Pan, Teresa Tsakok iD, Ruoheng Wei iD, Nick Dand iD, Floris C Loeff iD, Karien Bloem iD, Annick de Vries iD, David Baudry iD, Michael Duckworth iD, Angela Pushpa-Rajah iD, Alice Russell, Ali Alsharqi und 15 weitere

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70563 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 30.04.2026. Verfasst von Shan Pan und 26 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Drug Monitoring, Adalimumab, Psoriasis, Antirheumatic Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringAdalimumabPsoriasisAntirheumatic AgentsCost-Effectiveness AnalysisSeverity of Illness IndexStochastic ProcessesComputer SimulationDose-Response Relationship, DrugBayes TheoremTreatment OutcomeProspective StudiesHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and over

Stichwörter der Autor:innen

adalimumabpharmacokinetic‐pharmacodynamicpsoriasisreal‐worldtherapeutic drug monitoring

Substanzen

AdalimumabAntirheumatic Agents

Autor:innen und Institutionen

  • St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
  • Department of Medical and Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
  • Sanquin Diagnostic Services, Amsterdam, the Netherlands.
  • Dermatology Department, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK.
  • West Glasgow Ambulatory Care Hospital, Glasgow, UK.

ORCID-Profile: Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa-Rajah, Gabrielle Becher, Shyamal Wahie, Andrew Wright, Christopher E M Griffiths, Nick J Reynolds, Jonathan Barker, Richard B Warren, A David Burden, Theo Rispens, Satveer K Mahil, Joseph F Standing, Catherine H Smith

Zitieren

APA

Pan, S., Tsakok, T., Wei, R., Dand, N., Loeff, F. C., Bloem, K., de Vries, A., Baudry, D., Duckworth, M., Pushpa-Rajah, A., Russell, A., Alsharqi, A., Becher, G., Murphy, R., Wahie, S., Wright, A., Griffiths, C. E. M., Reynolds, N. J., Barker, J., …, & BSTOP Study Group and the PSORT Consortium (2026). Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70563

Vancouver

Pan S, Tsakok T, Wei R, Dand N, Loeff FC, Bloem K, et al. Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70563

BibTeX
@article{Pan2026,
  author = {Pan, Shan and Tsakok, Teresa and Wei, Ruoheng and Dand, Nick and Loeff, Floris C and Bloem, Karien and de Vries, Annick and Baudry, David and Duckworth, Michael and Pushpa-Rajah, Angela and Russell, Alice and Alsharqi, Ali and Becher, Gabrielle and Murphy, Ruth and Wahie, Shyamal and Wright, Andrew and Griffiths, Christopher E M and Reynolds, Nick J and Barker, Jonathan and Warren, Richard B and Burden, A David and Rispens, Theo and Mahil, Satveer K and Standing, Joseph F and Smith, Catherine H and BADBIR Study Group, BADBIR Study Group and BSTOP Study Group and the PSORT Consortium, BSTOP Study Group and the PSORT Consortium},
  title = {Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70563}
}
Kostenlos starten →